Go Pro
→ Trump’s New Currency Reset (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
$5.54
$5.55
$2.61
▼
$5.65
$290.24M1.25376,318 shsN/A
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
$32.14
-0.5%		$25.97
$3.05
▼
$33.67
$1.13B1.06427,539 shs874,487 shs
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$58.86
+44.3%		$39.06
$14.27
▼
$59.79
$1.61B0.86569,204 shs2.29 million shs
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$14.75
+9.4%		$13.23
$9.65
▼
$19.11
$1.27B1.761.71 million shs2.51 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
0.00%0.00%0.00%0.00%0.00%
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
0.00%+12.33%+17.72%+39.75%+926.81%
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
0.00%+31.97%+58.27%+94.51%+243.81%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
0.00%+6.19%+13.11%+19.43%+33.97%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
$5.54
$5.55
$2.61
▼
$5.65
$290.24M1.25376,318 shsN/A
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
$32.14
-0.5%		$25.97
$3.05
▼
$33.67
$1.13B1.06427,539 shs874,487 shs
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$58.86
+44.3%		$39.06
$14.27
▼
$59.79
$1.61B0.86569,204 shs2.29 million shs
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$14.75
+9.4%		$13.23
$9.65
▼
$19.11
$1.27B1.761.71 million shs2.51 million shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
0.00%0.00%0.00%0.00%0.00%
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
0.00%+12.33%+17.72%+39.75%+926.81%
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
0.00%+31.97%+58.27%+94.51%+243.81%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
0.00%+6.19%+13.11%+19.43%+33.97%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
0.00
N/AN/AN/A
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
2.55
Moderate Buy$36.6313.96% Upside
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
2.33
Hold$67.5014.68% Upside
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
2.89
Moderate Buy$44.38200.85% Upside

Current Analyst Ratings Breakdown

Latest ALIM, ANRO, EYPT, and ETON Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/14/2026
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$60.00 ➝ $68.00
8/14/2026
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
B. Riley Financial, Inc. logo
B. Riley Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$40.00 ➝ $70.00
8/14/2026
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$65.00 ➝ $70.00
8/13/2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
Wedbush logo
Wedbush
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetNeutral$24.00 ➝ $26.00
8/13/2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
BTIG Research logo
BTIG Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$28.00 ➝ $37.00
8/11/2026
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$57.00 ➝ $65.00
8/7/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Chardan Capital logo
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$65.00
8/6/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$47.00 ➝ $55.00
8/6/2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$30.00 ➝ $27.00
7/29/2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/28/2026
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
Craig Hallum logo
Craig Hallum
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$40.00 ➝ $62.00
(Data available from 8/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
$99.68M2.91N/AN/A$0.88 per share6.30
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/AN/AN/AN/A$6.25 per shareN/A
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$79.95M20.16$0.01 per share11,355.92$0.98 per share60.06
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
$31.37M40.54N/AN/A$1.93 per share7.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
-$20.13M-$1.57N/A26.38N/A-14.74%-33.70%-9.63%N/A
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$63.24M-$2.42N/AN/AN/AN/A-46.46%-39.09%N/A
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
-$4.60M$0.38154.8936.11N/A12.02%47.64%12.93%N/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$231.96M-$3.74N/AN/AN/A-10,994.73%-135.81%-108.35%11/4/2026 (Estimated)

Latest ALIM, ANRO, EYPT, and ETON Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
$0.1898$0.43+$0.2402$0.35$27.11 million$37.59 million
8/12/2026Q2 2026
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
-$0.7345-$0.65+$0.0845-$0.65N/AN/A
8/5/2026Q2 2026
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
-$1.01-$1.09-$0.08-$0.2720$0.45 million$0.51 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
N/AN/AN/AN/AN/A
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/AN/AN/AN/AN/A
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
N/AN/AN/AN/AN/A
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
1.80
2.79
2.62
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
0.07
14.85
20.52
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
0.62
1.21
0.88
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
N/A
4.50
4.46

Institutional Ownership

CompanyInstitutional Ownership
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
99.83%
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/A
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
27.86%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
99.41%

Insider Ownership

CompanyInsider Ownership
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
31.40%
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
11.25%
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
16.49%
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
5.13%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alimera Sciences, Inc. stock logo
ALIM
Alimera Sciences
15052.39 million35.94 millionNo Data
Alto Neuroscience, Inc. stock logo
ANRO
Alto Neuroscience
N/A35.09 million31.15 millionN/A
Eton Pharmaceuticals, Inc. stock logo
ETON
Eton Pharmaceuticals
2027.39 million22.88 millionOptionable
Eyepoint Pharmaceuticals, Inc. stock logo
EYPT
Eyepoint Pharmaceuticals
12086.21 million81.79 millionOptionable

Recent News About These Companies

EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 14 at 4:32 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/14/3345633/0/en/eyepoint-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html
Eyepoint Pharmaceuticals, Inc. $EYPT Stock Position Boosted by California State Teachers Retirement System
August 14 at 3:36 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-eyepoint-pharmaceuticals-inc-eypt-stock-position-boosted-by-california-state-teachers-retirement-system-2026-08-14/
Stock Traders Purchase Large Volume of Eyepoint Pharmaceuticals Put Options (NASDAQ:EYPT)
August 13 at 10:59 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/stock-traders-purchase-large-volume-of-eyepoint-pharmaceuticals-put-options-nasdaqeypt-2026-08-13/
Eyepoint Pharmaceuticals' (EYPT) Buy Rating Reiterated at Chardan Capital
August 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30951871
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of "Moderate Buy" by Analysts
August 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30951675
Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of "Moderate Buy" from Brokerages
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/eyepoint-pharmaceuticals-inc-nasdaqeypt-receives-average-recommendation-of-moderate-buy-from-brokerages-2026-08-10/
What is HC Wainwright's Estimate for EYPT Q3 Earnings?
August 10, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30951193
HC Wainwright Issues Negative Outlook for EYPT Earnings
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-issues-negative-outlook-for-eypt-earnings-2026-08-10/
RBC Capital Keeps Their Buy Rating on EyePoint Pharmaceuticals (EYPT)
August 9, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/EYPT/pressreleases/3715857/rbc-capital-keeps-their-buy-rating-on-eyepoint-pharmaceuticals-eypt/
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target Raised to $55.00
August 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30950672
HC Wainwright Cuts Eyepoint Pharmaceuticals (NASDAQ:EYPT) Price Target to $27.00
August 9, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30949900
EyePoint: Phase 3 Design Creates A More Valuable Durability Story
August 8, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4933744-eyepoint-phase-3-design-creates-a-more-valuable-durability-story
Eyepoint Pharmaceuticals' (EYPT) "Buy" Rating Reiterated at Chardan Capital
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/eyepoint-pharmaceuticals-eypt-buy-rating-reiterated-at-chardan-capital-2026-08-07/
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Announces Quarterly Earnings Results
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/eyepoint-pharmaceuticals-nasdaqeypt-announces-quarterly-earnings-results-2026-08-06/
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Given New $55.00 Price Target at Cantor Fitzgerald
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/eyepoint-pharmaceuticals-nasdaqeypt-given-new-5500-price-target-at-cantor-fitzgerald-2026-08-06/
HC Wainwright Issues Pessimistic Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-issues-pessimistic-forecast-for-eyepoint-pharmaceuticals-nasdaqeypt-stock-price-2026-08-06/
EyePoint (EYPT) Reports Q2 Loss, Beats Revenue Estimates
August 5, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2968413/eyepoint-eypt-reports-q2-loss-beats-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2968413
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
August 5, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/05/3339189/0/en/eyepoint-reports-second-quarter-2026-financial-results-and-highlights-recent-corporate-developments.html
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 5.3% - Here's Why
August 4, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/eyepoint-pharmaceuticals-nasdaqeypt-trading-down-53-heres-why-2026-08-04/
Janus Henderson Group PLC Grows Stock Position in Eyepoint Pharmaceuticals, Inc. $EYPT
August 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-janus-henderson-group-plc-grows-stock-position-in-eyepoint-pharmaceuticals-inc-eypt-2026-08-02/
Swiss National Bank Takes Position in Eyepoint Pharmaceuticals, Inc. $EYPT
July 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-swiss-national-bank-takes-position-in-eyepoint-pharmaceuticals-inc-eypt-2026-07-31/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alimera Sciences stock logo

Alimera Sciences NASDAQ:ALIM

Alimera Sciences, Inc., a pharmaceutical company, develops and commercializes prescription ophthalmic retinal pharmaceuticals. It operates through United States, International, and Operating Cost segments. The company offers ILUVIEN, a fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). It also provides YUTIQ, a fluocinolone acetonide intravitreal implant to treat NIU-PS. The company sells its products to physician offices, clinics, pharmacies, and hospitals through direct sales and distributors. It has a collaboration agreement with EyePoint Pharmaceuticals US, Inc. to develop, manufacture, and sell products including YUTIQ for the treatment and prevention of uveitis; and Ocumension (Hong Kong) Limited for the development and commercialization of the company's 190 microgram fluocinolone acetonide intravitreal implant in applicator for the treatment and prevention of eye diseases. Alimera Sciences, Inc. was incorporated in 2003 and is headquartered in Alpharetta, Georgia.

Alto Neuroscience stock logo

Alto Neuroscience NYSE:ANRO

$32.14 -0.16 (-0.50%)
Closing price 08/14/2026 03:59 PM Eastern
Extended Trading
$32.10 -0.03 (-0.11%)
As of 08/14/2026 07:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder. The company develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties which is in phase 2b clinical trial to treat patients with MDD; ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor which is in phase 1 clinical trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist which is in phase 1 clinical trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor which is in phase 1 clinical trial for the treatment of MDD. In addition, it develops novel pharmacodynamically synergistic combination and biomarker platform that collects patient-specific data to identify biomarker-characterized patient. The company was incorporated in 2019 and is headquartered in Los Altos, California.

Eton Pharmaceuticals stock logo

Eton Pharmaceuticals NASDAQ:ETON

$58.86 +18.06 (+44.26%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$59.49 +0.63 (+1.07%)
As of 08/14/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Eyepoint Pharmaceuticals stock logo

Eyepoint Pharmaceuticals NASDAQ:EYPT

$14.75 +1.27 (+9.42%)
Closing price 08/14/2026 04:00 PM Eastern
Extended Trading
$15.00 +0.25 (+1.69%)
As of 08/14/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas